127 related articles for article (PubMed ID: 33974884)
1. Population-Level Uptake of Moderately Hypofractionated Definitive Radiation Therapy in the Treatment of Prostate Cancer.
Nithiyananthan K; Creighton N; Currow D; Martin JM
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):417-423. PubMed ID: 33974884
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer.
Faria S; Ruo R; Perna M; Cury F; Duclos M; Sarshoghi A; Souhami L
Pract Radiat Oncol; 2020; 10(6):e514-e520. PubMed ID: 32738465
[TBL] [Abstract][Full Text] [Related]
4. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
5. The Pattern of Use of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer in New South Wales, Australia, 2008 to 2012.
Delaney GP; Gandhidasan S; Walton R; Terlich F; Baker D; Currow D
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):266-272. PubMed ID: 27473814
[TBL] [Abstract][Full Text] [Related]
6. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
8. Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.
Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):823-833. PubMed ID: 30458234
[TBL] [Abstract][Full Text] [Related]
9. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy.
Faria S; Ruo R; Cury F; Duclos M; Souhami L
Pract Radiat Oncol; 2017; 7(4):264-269. PubMed ID: 28222995
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Sujenthiran A; Parry M; Nossiter J; Berry B; Cathcart PJ; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):501-508. PubMed ID: 32143901
[TBL] [Abstract][Full Text] [Related]
11. Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORT Palliative Studies.
Chatterjee S; Chakrabarty S; Santosham R; Saha A; Mallick I; Arunsingh M; Bhattacharya T; Achari R; Agrawal S; Ahmed R; Das J; Mahata A; Mandal S; Ray S
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1033-1042. PubMed ID: 36868522
[TBL] [Abstract][Full Text] [Related]
12. Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.
Mallick I; Das A; Arunsingh M
Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):260-264. PubMed ID: 30718087
[TBL] [Abstract][Full Text] [Related]
13. Adoption of hypofractionated radiation therapy for early breast cancer in private practice: the GenesisCare experience 2014–2016.
Neville K; Dreosti M; Blakey D; Latham M; Izard MA; Young S; Graham G; O'Brien P
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):127-133. PubMed ID: 31602814
[TBL] [Abstract][Full Text] [Related]
14. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results.
Cury FL; Duclos M; Aprikian A; Patrocinio H; Kassouf W; Shenouda G; Faria S; David M; Souhami L
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1417-23. PubMed ID: 21784585
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted moderate hypofractionation of prostate cancer : A prospective analysis of acute toxicity, QOL and outcome in 221 patients.
Schörghofer A; Groher M; Karner J; Kopp A; Kametriser G; Kunit T; Holzinger J; Sedlmayer F; Wolf F
Strahlenther Onkol; 2019 Oct; 195(10):894-901. PubMed ID: 31139841
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.
Morgan SC; Hoffman K; Loblaw DA; Buyyounouski MK; Patton C; Barocas D; Bentzen S; Chang M; Efstathiou J; Greany P; Halvorsen P; Koontz BF; Lawton C; Leyrer CM; Lin D; Ray M; Sandler H
Pract Radiat Oncol; 2018; 8(6):354-360. PubMed ID: 30322661
[TBL] [Abstract][Full Text] [Related]
17. Journey to hypofractionation in radiotherapy for breast cancer: critical reviews for recent updates.
Kim N; Kim YB
Radiat Oncol J; 2022 Dec; 40(4):216-224. PubMed ID: 36606299
[TBL] [Abstract][Full Text] [Related]
18. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis.
Malouff TD; Stross WC; Seneviratne DS; Waddle MR; May BC; Buskirk SJ; Tzou KS
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):349-355. PubMed ID: 31780782
[TBL] [Abstract][Full Text] [Related]
19. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
Morgan SC; Hoffman K; Loblaw DA; Buyyounouski MK; Patton C; Barocas D; Bentzen S; Chang M; Efstathiou J; Greany P; Halvorsen P; Koontz BF; Lawton C; Leyrer CM; Lin D; Ray M; Sandler H
J Urol; 2019 Mar; 201(3):528-534. PubMed ID: 30759696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
